1. Pink Sheet

Two Companies, Two BARDA Contracts, Two Approaches To Coronavirus

 
• By Brenda Sandburg

Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.

PS2002_Corona virus vaccine_1630992484_1200.jpg
HHS is collaborating with Sanofi on coronarvirus vaccine candidate using platform in Flublok

Sanofi Pasteur is partnering with the Biomedical Advanced Research and Development Authority (BARDA) to develop a potential vaccine for the coronavirus COVID-19 that utilizes the same recombinant DNA platform used in its influenza vaccine Flublok and in its previous vaccine candidate for severe acute respiratory syndrome (SARS).

Announcing the collaboration in a 18 February press call, David Loew, Sanofi's global head of vaccines, said leveraging this previous...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.